Canada : Toronto Public Health confirms this year's first positive mosquito test for West Nile Virus Translate.
Toronto Public Health has received lab confirmation that mosquitoes in the city have tested positive for West Nile Virus. This is the first positive mosquito test for West Nile Virus in Toronto in 2017.
"While the risk of becoming infected with West Nile Virus in Toronto is low, now is a good time to remind residents of the ways they can protect themselves from mosquito bites and help reduce the risk of infection," said Dr. Eileen de Villa, Toronto's Medical Officer of Health.
Toronto Public Health recommends the following prevention tips to protect residents from mosquito bites:
Wear light-coloured, long-sleeved shirts and pants when outdoors. Apply insect repellent containing DEET or icaridin and follow the manufacturer's instructions. Take extra care during peak mosquito biting time (dusk and dawn) by using mosquito repellent and wearing protective clothing. Remove standing water from your property, where mosquitoes can breed.Ensure your home has tight-fitting screens on windows and doors.
Once a week, from mid-June until mid-September, Toronto Public Health sets 40 mosquito traps across the city. The mosquitoes collected are submitted to a laboratory for identification and testing for West Nile Virus. As part of the City of Toronto's West Nile Virus mosquito reduction program, city catch basins are treated with larvicide to reduce mosquito breeding.
In 2016, Toronto Public Health reported 38 positive mosquito tests and 19 confirmed human cases of West Nile Virus. To date in 2017, there have been no human cases of West Nile Virus reported in Toronto.
[c] 2017 Al Bawaba (Albawaba.com) Provided by SyndiGate Media Inc. ( Syndigate.info ).
|Printer friendly Cite/link Email Feedback|
|Date:||Jul 7, 2017|
|Previous Article:||United States : Titan Pharmaceuticals and Walter Reed Army Institute of Research Collaborate to Evaluate ProNeura Antimalarial Implants.|
|Next Article:||United States : Bristol-Myers Squibbs ORENCIA (abatacept) Receives FDA Approval for Treatment of Active Psoriatic Arthritis (PsA) in Adults.|